Simcere Pharmaceutical Group (HKG:2096) reported a 2.6% increase in profit attributable to equity shareholders for 2024 to 733.2 million yuan, from 714.8 million yuan in the previous year, according to a filing with the Hong Kong bourse on Monday.
Earnings per share grew to 0.29 yuan from 0.27 yuan a year ago. Analysts polled by Visible Alpha estimated EPS at 0.35 yuan.
Revenue for the year increased marginally by 0.4% to 6.64 billion yuan, from 6.61 billion yuan in the prior year. Analysts polled by Visible Alpha estimated revenue at 6.71 billion yuan.
The board declared a final dividend of 0.16 yuan per share, subject to shareholders' approval. The final dividend is expected to be paid on or before July 14 to shareholders on record as of June 24.
The company's shares were down nearly 3% in recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。